Gilead Sciences Inc
NASDAQ: GILD
$111.44
-$1.11 (-1.0%)
Closing Price on March 14, 2025
GILD Articles
May 19, 2016: Here are four stocks trading with heavy volume among 81 equities making new 52-week lows in Thursday’s session. NYSE decliners led advancers by nearly 2 to 1 while Nasdaq decliners...
Published:
Last Updated:
The short interest data are out for the April 29 settlement date, and short interest moves were mixed in these selected biotech stocks.
Published:
Last Updated:
Gilead Sciences saw a sell-off after the company posted less than favorable earnings, but one analyst thinks that investors have spoken too soon.
Published:
Last Updated:
With earnings having just been released for some of the top biotech companies, we saw a flurry of analyst calls by the week's end.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Friday morning include Amazon, Ford, Gilead, Level 3, Sarepta, Western Digital and Whiting Petroleum.
Published:
Last Updated:
Gilead Sciences Inc. (NASDAQ: GILD) reported first-quarter financial results after the markets closed on Thursday. The company had $3.03 in earnings per share (EPS) on $7.79 billion in revenue...
Published:
Last Updated:
The April 15 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Published:
Last Updated:
Attaining a certain drug can mean the difference between life and death for millions of Americans. These essential products also help generate billions for drug manufacturers. Pharmaceutical...
Published:
Last Updated:
In a recent report, UBS made some significant changes to its Equity Focus list. The analysts look to go a touch more aggressive with the new additions.
Published:
Last Updated:
The March 31 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Published:
Last Updated:
Despite a modest erosion to fundamentals and sector headwinds, Jefferies does not anticipate any dramatic earnings misses, which could help sentiment continue to turn around.
Published:
Last Updated:
Ionis Pharmaceuticals led biotech stocks early on Wednesday following a key patent dispute win in the U.S. court system.
Published:
Last Updated:
Argus reiterated Gilead Sciences as Buy, but hat really matters here is that Argus has a $150 price target on the stock.
Published:
Last Updated:
The February 29 short interest data have been compared with the previous report, and short interest decreased across the board in these selected biotech stocks.
Published:
Last Updated:
Here are two big biopharmas, both with multibillion dollar portfolios and both of which have lost a combined $113 billion in market cap since August.
Published:
Last Updated:
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.